Principal CADD Scientist
ML + Compchem + Software
hybrid: Burlingame
Salary 1
added Wed Sep 27, 2023
Apply to Genesis TherapeuticsGenesis Therapeutics is building a world-class computational team to accelerate drug discovery through machine learning and biophysical simulation. We are looking for computational chemists experienced in structure-based drug design to help drive rapid progress in our drug programs and play a critical role in developing our ML/MD platform.
You will
- Work directly on multiple small molecule drug discovery programs across a varied target portfolio, including novel targets with little-to-no known chemical matter
- Utilize off-the-shelf molecular design tools, as well as custom-built internal tools, to analyze protein-ligand structures and MD simulations
- Work closely with our AI, software, compchem, and medchem teams to drive methods development on our ML/MD platform
You are
- A PhD-level computational chemist with deep understanding of protein-ligand binding interactions
- Proficient with one-or-more off-the-shelf tools for structure-based drug design, such as MOE, Pymol, and Schrodinger Suite
- 3+ years of experience as a computational chemist / CADD scientist at pharma or biotech, using structure-based methods on active drug discovery programs
What we offer
- The opportunity to work on high impact tools and products that are immediately deployed to accelerate the discovery of new medicines
- Strong technical coworkers in AI, software, compchem, and medchem, who all have a powerful mix of intellectual curiosity and humility
- Competitive salary and equity. Medical, dental, and vision insurance, and a 401(k) program
We started Genesis Therapeutics in 2019 with origins in field-leading AI + biophysics research. Since then, we’ve dramatically accelerated innovation in Machine Learning and molecular simulation technologies for drug discovery, with the goal of providing new treatments for patients with severe diseases.
We are a mission-driven group of researchers, engineers, and drug developers. We believe close-knit, interdisciplinary collaboration is crucial for inventing important new technology and rapidly advancing optimal therapies.